{"altmetric_id":15977349,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Corcept Therapeutics"],"first_seen_on":"2017-01-31T08:12:33+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1485842460,"links":["https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02922257"],"nct_id":"NCT02922257","pubdate":"2016-09-27T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery","type":"clinical_trial_study_record"},"altmetric_score":{"score":7,"score_history":{"1y":7,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7},"context_for_score":{"all":{"total_number_of_other_articles":8156965,"mean":6.8933631772734,"rank":1168068,"this_scored_higher_than_pct":84,"this_scored_higher_than":6914836,"rank_type":"exact","sample_size":8156965,"percentile":84},"similar_age_3m":{"total_number_of_other_articles":262601,"mean":12.836830121858,"rank":57328,"this_scored_higher_than_pct":76,"this_scored_higher_than":201800,"rank_type":"exact","sample_size":262601,"percentile":76},"this_journal":{"total_number_of_other_articles":23214,"mean":10.503012363762,"rank":3911,"this_scored_higher_than_pct":75,"this_scored_higher_than":17416,"rank_type":"exact","sample_size":23214,"percentile":75},"similar_age_this_journal_3m":{"total_number_of_other_articles":736,"mean":13.986710204082,"rank":80,"this_scored_higher_than_pct":85,"this_scored_higher_than":626,"rank_type":"exact","sample_size":736,"percentile":85}}},"demographics":[],"counts":{"total":{"posts_count":1},"news":{"unique_users_count":1,"unique_users":["bioportfolio"],"posts_count":1}},"posts":{"news":[{"title":"Corcept Therapeutics (CORT) Preliminary Facts for Q4-2016 and Early 2017 Guidance","url":"http:\/\/ct.moreover.com\/?a=29418159426&p=1pl&v=1&x=z_35e60ca8lFo95NFBRKLg","license":"public","citation_ids":[15977349,15977353,4366506],"posted_on":"2017-01-31T06:01:00+00:00","summary":"Printed From BioPortfolio.com We recently wrote a brief update about Corcept. We documented Corcept\u2019s growing portfolio of positive results across an array of indications in Phase IIa trials.","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}}]}}